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Introduction {#sec001}
============

Small cell lung cancer (SCLC) is a highly malignant neuroendocrine tumor, accounting for 15--20% of lung cancer cases \[[@pone.0230979.ref001]\]. Compared with non-small cell lung cancer, SCLC exhibits more aggressive invasiveness, earlier distant metastasis, and poorer prognosis. Despite the continuous development of medical technology, the prognosis of SCLC is still not optimistic, and the median overall survival is often less than 6 months\[[@pone.0230979.ref002]\]. Thus, the identification of novel biomarkers for predicting prognosis is essential for improving long-term outcomes. Although some new biomarkers have been shown to be independent prognostic factors for SCLC\[[@pone.0230979.ref003], [@pone.0230979.ref004]\], most of these biomarkers are expensive and time-consuming to detect. Therefore, identification of inexpensive and simple biomarkers for SCLC may have important clinical implications.

In recent years, the association between systemic inflammation and tumors has become an essential research hotspot. Many studies have shown that inflammation is involved in all aspects of tumor development\[[@pone.0230979.ref005], [@pone.0230979.ref006]\]. The neutrophil-to-lymphocyte ratio (NLR) is a simple, widely available clinical indicator of inflammation and has been shown to be associated with the prognosis of a variety of malignant tumors\[[@pone.0230979.ref007]--[@pone.0230979.ref009]\]. Recently, many scholars have evaluated the relationships between pretreatment NLR and prognosis in patients with SCLC; however, the conclusions have been inconsistent.

Therefore, we conducted this meta-analysis in order to assess the clinicopathological and prognostic value of the pretreatment NLR in SCLC.

Materials and methods {#sec002}
=====================

Search strategies {#sec003}
-----------------

We searched the PubMed, Embase, Cochrane Library, Web of Science, Chinese Biomedical Literature, China National Knowledge Infrastructure (CNKI), and Wanfang databases. The search was performed using a combination of the following technical terms: ("Neutrophil-lymphocyte ratio" OR NLR OR "Neutrophil lymphocyte ratio" OR "Neutrophil to lymphocyte ratio") and ("Lung Cancer" OR "Lung Carcinoma" OR "Small Cell Lung Cancer" OR "Oat Cell Lung Cancer" OR "Small Cell Cancer Of The Lung" OR "Carcinoma, Small Cell Lung" OR "Oat Cell Carcinoma of Lung" OR \"Small Cell Lung Carcinoma\"). The search time limit was from the time of establishment of the database to February 1, 2020. There was no geographical restriction on the literature search; however, only Chinese and English studies were considered. Additionally, the references included in the literature were retrieved to avoid missing detection.

Inclusion and exclusion criteria {#sec004}
--------------------------------

The inclusion criteria were as follows: (1) the subject was a patient who had been diagnosed with SCLC; (2) the pretreatment NLR value was obtained; (3) the purpose of the study was to explore the relationships between NLR and OS or PFS in SCLC; (4) the hazard ratio (HR) and 95% confidence interval (95% CI) were reported in the literature; and (5) the language of the document was English or Chinese.

The exclusion criteria were as follows: (1) case reports, letters, reviews, meta-analyses, and conference reports; (2) duplicate publications; and (3) unable to obtain the full text or data from the text.

Data extraction and quality assessment {#sec005}
--------------------------------------

Two authors independently used the Newcastle-Ottawa Scale (NOS) \[[@pone.0230979.ref010]\] to assess the quality of the studies. If the authors disagreed, the disagreement was resolved through discussion. The following data were extracted: first author, publication year, country, ethnicity, age, sample size, follow-up (months), median OS (months), cut-off value, clinical stage (limited stage or/and extensive stage)\[[@pone.0230979.ref011]\], type of survival analysis, and outcome. The study was considered to be of high quality when the NOS score was greater than or equal to 6.

Statistical analysis {#sec006}
--------------------

The HR and 95% CI were pooled to assess the prognostic value of NLR for patients with SCLC. Evaluation of the clinicopathological significance of NLR in SCLC used odds ratios (ORs) and 95% confidence intervals (95% CIs). We used Cochran's Q statistic test and then analyzed the heterogeneity between studies based on I^2^ and *P* values \[[@pone.0230979.ref012]\]. According to the Cochrane Handbook \[[@pone.0230979.ref013]\], when I^2^ was less than or equal to 50% and the *P*-value was greater than 0.10, the heterogeneity was acceptable. When the different studies included were not heterogeneous, they were combined using a fixed-effects model; otherwise, random-effects models were used \[[@pone.0230979.ref014]\], and subgroup analyses \[[@pone.0230979.ref015]\] and meta-regression \[[@pone.0230979.ref016]\] were used to discuss heterogeneity sources. When the combined HR was greater than 1, the survival rate was poor. If the 95% CI did not contain 1, the result was considered statistically significant. Sensitivity analysis was also needed to assess whether the results were stable. At the same time, quantitative analysis of publication bias was performed using Begg's tests \[[@pone.0230979.ref017]\] and Egger's tests \[[@pone.0230979.ref018]\], and if necessary, the trim and fill method \[[@pone.0230979.ref019]\] was used to quantitatively analyze publication bias. Results with *P* values of less than 0.05 were considered statistically significant. Stata 12.0 statistical analysis software (Stata Corporation, College Station, TX, USA) and Review Manager software (version 5.3; Cochrane Collaboration, London, UK) were used for all studies.

Results {#sec007}
=======

Study search {#sec008}
------------

In total, 1686 studies were retrieved according to the search strategy. According to the inclusion and exclusion criteria, after reviewing duplicates and screening the titles or abstracts, 59 research articles were evaluated. Finally, 20 eligible studies were included \[[@pone.0230979.ref020]--[@pone.0230979.ref039]\], with 21 outcomes. The flow chart for the study is shown in [Fig 1](#pone.0230979.g001){ref-type="fig"}.

![The flow chart of the study selection process.](pone.0230979.g001){#pone.0230979.g001}

Study characteristics {#sec009}
---------------------

This meta-analysis included 5141 patients with SCLC (3461 men and 1680 women). The number of patients in each study ranged from 52 to 919, with a median of 172. The cut off value of NLRs ranged from 2.258 to 5.0, with a median of 3.70. The main characteristics of the incorporated literature are shown in [Table 1](#pone.0230979.t001){ref-type="table"}.

10.1371/journal.pone.0230979.t001

###### Characteristics of all included studies in the meta-analysis.

![](pone.0230979.t001){#pone.0230979.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author                           Year   Country   Ethnicity   Age\                 Sample Size   Follow-up (months)   Median OS\   Cut off   Clinical\   Survival analysis   Outcome   NOS
                                                                      (range and median)                                      (months)               stage                                     
  -------------------------------------- ------ --------- ----------- -------------------- ------------- -------------------- ------------ --------- ----------- ------------------- --------- -----
  Ju\[[@pone.0230979.ref020]\]           2018   China     Asian       NR                   154           NR                   NR           3.70      L+E         M                   OS        8

  Wang (1)\[[@pone.0230979.ref021]\]     2017   China     Asian       31--83               172           NR                   19.18        3.86      L+E         M                   OS        7

  Huang\[[@pone.0230979.ref022]\]        2016   China     Asian       31--88               112           NR                   NR           4.50      L+E         M                   OS        8

  Zhang\[[@pone.0230979.ref023]\]        2017   China     Asian       59 (30--78)          265           NR                   16           4.0       L+E         M                   OS        8

  Wang (2)\[[@pone.0230979.ref024]\]     2016   China     Asian       62 (28--79)          153           NR                   23.3         3.20      L+E         M                   OS/PFS    8

  Wang (3)\[[@pone.0230979.ref025]\]     2017   China     Asian       NR                   181           NR                   NR           3.60      L+E         M                   OS        8

  Bernhardt\[[@pone.0230979.ref026]\]    2018   Germany   Caucasian   64 (37--93)          350           NR                   20           4.0       L           U                   OS        7

  Murray\[[@pone.0230979.ref027]\]       2014   UK        Caucasian   61.6\                52            26.1                 21.1         5         L           M                   OS        6
                                                                      (38.3--77.4)                                                                                                             

  Hong\[[@pone.0230979.ref028]\]         2015   China     Asian       56 (16--84)          919           NR                   10.4         5         L+E         M                   OS        8

  Sakin\[[@pone.0230979.ref029]\]        2019   Turkey    Caucasian   61 (35--83)          113           6 (1--33)            NR           3         E           M                   OS        8

  Suzuki {1}\[[@pone.0230979.ref030]\]   2018   USA       Caucasian   63                   252           NR                   11.0         4.0       E           M                   OS        8

  Wang (4)\[[@pone.0230979.ref031]\]     2014   China     Asian       NR                   114           NR                   14           3         L+E         M                   OS        8

  Xie ①\[[@pone.0230979.ref032]\]        2015   China     Asian       68 (27--91)          555           10.8                 NR           5         E           M                   OS        8

  Xie ②\[[@pone.0230979.ref032]\]        2015   China     Asian       68 (27--91)          383           10.8                 NR           5         L           M                   OS        8

  Suzuki {2}\[[@pone.0230979.ref033]\]   2018   USA       Caucasian   65                   122           NR                   16.6         2.9       L           M                   OS        7

  Käsmann\[[@pone.0230979.ref034]\]      2017   Germany   Caucasian   NR                   65            NR                   20           4.0       L           M                   OS        8

  Deng\[[@pone.0230979.ref035]\]         2017   China     Asian       58 (24--81)          320           39.1                 13.8         2.65      L+E         M                   OS/PFS    8

  Lohinai\[[@pone.0230979.ref036]\]      2019   Hungary   Caucasian   58                   155           NR                   NR           2.258     L+E         M                   OS        7

  Wang (5)\[[@pone.0230979.ref037]\]     2019   China     Asian       58(39--71)           228           46                   20           2.3       L+E         M                   OS/PFS    8

  Li\[[@pone.0230979.ref038]\]           2019   China     Asian       NR                   160           NR                   NR           2.32      L+E         M                   OS        7

  Liu\[[@pone.0230979.ref039]\]          2019   China     Asian       59                   316           NR                   11           2.68      L+E         M                   OS        8
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(1)--(5): different authors and different studies; {1}--{2}: the same author but different studies; ①--②: the same author and the same study; L: limited stage; E: extensive stage; M: multivariate; U: univariate; NR: not reported; NOS: Newcastle-Ottawa scale

The prognostic value of the pretreatment NLR in SCLC {#sec010}
----------------------------------------------------

According to the included literature, 20 studies provided data on OS related to pretreatment NLR in patients with SCLC. As shown in [Fig 2](#pone.0230979.g002){ref-type="fig"}, a high pretreatment NLR was closely related to poor OS (HR = 1.40, 95% CI = 1.26--1.55, *P* \< 0.00001; I^2^ = 64%; [Fig 2](#pone.0230979.g002){ref-type="fig"}). In the heterogeneity analysis, significant heterogeneity was observed among the included studies. Therefore, subgroup and meta-regression analyses were required to explore the source of heterogeneity.

![Forest plot of HR for the association of pretreatment NLR in patients with SCLC.\
(A) OS; (B) PFS.](pone.0230979.g002){#pone.0230979.g002}

Data on PFS related to pretreatment NLR in patients with SCLC were provided by 3 studies. The pooled result showed that high pretreatment NLR was closely related to PFS (HR = 1.55, 95% CI = 1.27--1.88, *P* \< 0.0001; I^2^ = 0%) ([Fig 2](#pone.0230979.g002){ref-type="fig"}).

The pretreatment NLR and clinicopathological features of SCLC {#sec011}
-------------------------------------------------------------

As shown in [Table 2](#pone.0230979.t002){ref-type="table"}, the pretreatment NLR was significantly associated with clinical stage of SCLC (OR = 2.14, 95% CI = 1.35--3.39, *P* = 0.001). However, significant association between the pretreatment NLR and SCLC was not found in sex, age, and smoking.

10.1371/journal.pone.0230979.t002

###### The association between NLR and clinicopathological features of SCLC.

![](pone.0230979.t002){#pone.0230979.t002g}

  Variables                        Studies   OR \[95% CI\]         *P* value   Heterogeneity   Model   
  -------------------------------- --------- --------------------- ----------- --------------- ------- --------
  \(1\) Sex (Male vs. Female)      9         0.75 \[0.50--1.15\]   0.19        63              0.006   random
  \(2\) Age (≥ 60 vs. \< 60)       4         0.81 \[0.38--1.73\]   0.58        80              0.002   random
  \(3\) Clinical stage (E vs. L)   7         2.14 \[1.35--3.39\]   0.001       67              0.005   random
  \(4\) Smoking (Yes vs. No)       6         0.98 \[0.63--1.51\]   0.92        53              0.06    random

L:limited stage; E:extensive stage

Subgroup and meta-regression analyses {#sec012}
-------------------------------------

To elucidate the source of heterogeneity between studies, we performed subgroup analyses by clinical stage, ethnicity, cut-off values for NLR, and sample size ([Table 3](#pone.0230979.t003){ref-type="table"}). Through subgroup analysis, the prognostic role of pretreated NLR in OS did not change significantly ([Table 3](#pone.0230979.t003){ref-type="table"}), and significant heterogeneity remained between most subgroups. We used meta-regression analysis for quantitative analysis. The results of the univariate analysis revealed that sample size (*p*~3~ = 0.017) partly explained the source of heterogeneity ([Table 3](#pone.0230979.t003){ref-type="table"}). Multivariate analysis (*p*~3~ = 0.031) also showed that the sample size may be the main source of heterogeneity ([Table 3](#pone.0230979.t003){ref-type="table"}).

10.1371/journal.pone.0230979.t003

###### Subgroup and meta-regression analyses between NLR and OS.

![](pone.0230979.t003){#pone.0230979.t003g}

  Variables              Number of outcomes   HR \[95% CI\]         *P* value    Heterogeneity   Model       *P*~3~-value of Meta-regression           
  ---------------------- -------------------- --------------------- ------------ --------------- ----------- --------------------------------- ------- -------
  \(1\) Ethnicity                                                                                                                              0.329   0.762
  Asian                  14                   1.35 \[1.22--1.51\]   \< 0.00001   61              0.001       random                                    
  Caucasian              7                    1.40 \[1.16--2.21\]   0.005        71              0.002       random                                    
  \(2\) Cut-off value                                                                                                                          0.659   0.476
  \< 4.0                 12                   1.30 \[1.21--1.39\]   \< 0.00001   40              0.08        fixed                                     
  ≥ 4.0                  9                    1.36 \[1.11--1.67\]   0.003        78              \< 0.0001   random                                    
  \(3\) Sample size                                                                                                                            0.017   0.031
  N \< 150               6                    1.89 \[1.50--2.38\]   \< 0.00001   0               0.73        fixed                                     
  150 \< N ≤ 200         6                    1.26 \[1.16--1.36\]   \< 0.00001   30              0.21        fixed                                     
  N \> 200               9                    1.34 \[1.11--1.59\]   0.002        77              \< 0.0001   random                                    
  \(4\) Clinical stage                                                                                                                         0.563   0.925
  L                      5                    1.47 \[1.03--2.10\]   0.04         75              0.003       random                                    
  E                      3                    1.51 \[1.08--2.10\]   0.02         72              0.03        random                                    
  L + E                  13                   1.38 \[1.22--1.57\]   \< 0.00001   61              0.002       random                                    

L:limited stage; E:extensive stage

Sensitivity analysis {#sec013}
--------------------

We conducted a sensitivity analysis to assess whether individual studies affected the overall analysis. Our results showed that any of the studies could be removed, and the remaining HRs of the combined studies remained within the 95% CI of the combined HR in the meta-analysis ([Fig 3](#pone.0230979.g003){ref-type="fig"}). These findings indicated that the meta-analysis had good stability.

![Sensitivity analysis of the relationship between pretreatment NLR and OS in patients with SCLC.](pone.0230979.g003){#pone.0230979.g003}

Publication bias and the trim and fill method {#sec014}
---------------------------------------------

Quantitative analysis of publication bias was performed using the Begg method and the Egger method. The results showed the presence of a significant publication bias (Begg's test: *P* = 0.015; Egger's test: *P* = 0.015; [Fig 4](#pone.0230979.g004){ref-type="fig"}). Therefore, we used the trim and fill method to estimate the asymmetry in the funnel plot. After filling four unpublished studies by calculation, the funnel plot was symmetrical ([S1 Text](#pone.0230979.s003){ref-type="supplementary-material"}). No statistically significant change was observed in the results ([Fig 5](#pone.0230979.g005){ref-type="fig"}).

![Funnel plot for analysis of publication bias.\
(A) Funnel plot developed using the Egger method; (B) funnel plot using the Begg method.](pone.0230979.g004){#pone.0230979.g004}

![Funnel plot adjusted by the trim and fill method.](pone.0230979.g005){#pone.0230979.g005}

Discussion {#sec015}
==========

The tumor-associated inflammatory response is a potential prognostic indicator prior to treatment, manifesting as peripheral blood neutrophilia and relative lymphopenia \[[@pone.0230979.ref040]\]. Pretreatment NLR is readily available to assess the prognosis of patients with SCLC without high costs, allowing patients and physicians to make informed decisions before clinical treatment.

By pathological typing, lung cancer can be divided into small cell lung cancer and non-small cell cancer. Small cell lung cancer is a separate category, which has special biological behavior and clinical characteristics. Previous meta-analyses\[[@pone.0230979.ref041], [@pone.0230979.ref042]\] have focused on the relationships between NLR and prognosis in patients with non-small cell lung cancer. Additionally, the prior meta-analyses of SCLC \[[@pone.0230979.ref043], [@pone.0230979.ref044]\] only included two studies, which have not explored the clinicopathological value of NLR in SCLC. In our current meta-analysis, the conclusions presented herein identified 16 studies with 17 outcomes, most of which were published in the last two years and showed pretreatment NLR could provide a clinical reference for predicting prognosis in patients with SCLC.

The meta-analysis assessed the clinicopathological and prognostic value of the pretreatment NLR in SCLC. The results suggested that pretreatment NLR levels were inversely proportional to PFS and OS (PFS, HR = 1.55, 95% CI = 1.27--1.88, *P* \< 0.0001; I^2^ = 0%; OS, HR = 1.40, 95% CI = 1.26--1.55, *P* \< 0.00001; I^2^ = 64%). However, although the pooled result of PFS with only includes two studies has no apparent heterogeneity, the result requires larger sample studies to validate. At the same time, the Pooling analysis found a significant association between pretreatment NLR and clinical stage. High pretreatment NLR is a risk factor for extensive-stage small cell lung cancer.

However, this meta-analysis also had some limitations. First, significant heterogeneity was observed. The main source of heterogeneity by meta-regression analysis was the sample size. Subgroup and sensitivity analyses were used to confirm that the results of this meta-analysis were stable. Second, the papers showed publication bias, and affirmative results are easier to publish. Importantly, however, after correction with the trim and fill method, there were no changes in the prognostic value of pretreatment NLR in patients with SCLC. Finally, the clinical data between pretreatment NLR and PFS with SCLC is relatively small. Therefore, more large-scale prospective studies are needed.

Conclusion {#sec016}
==========

The meta-analysis showed that high pretreatment NLR was a risk factor for extensive-stage small cell lung cancer. Moreover, high levels of pretreatment NLR were significantly associated with reduced PFS and OS in patients with SCLC and that NLR was readily available and less costly, suggesting that NLR could be used as a biomarker for the prognosis of SCLC.
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